Clinical Decision Making in Multiple Myeloma: CAR-T in the 2nd Line Treatment Setting

Medical experts examine the factors that make Sarah an ideal candidate for CAR-T therapy in the second-line setting, focusing on how her age, fitness, and early relapse influence treatment decisions and exploring alternative options.

EP: 1.Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel

Now Viewing

EP: 2.Clinical Decision Making in Multiple Myeloma: CAR-T in the 2nd Line Treatment Setting

EP: 3.Ide-cel vs. Cilta-cel: Tailoring CAR T in Myeloma

EP: 4.Sarah’s Journey Through CAR-T Therapy: Pre-, Peri-, and Post-Treatment Considerations with Ide-cel

EP: 5.Getting to Know Robert, a 72-Year-Old Retired Teacher Facing a Myeloma Relapse and Considering CAR-T Therapy with Cilta-cel

EP: 6.Data and Expert Considerations Supporting Cilta-cel as Second-Line Treatment for Robert

EP: 7.Strategic Choices in CAR T for Myeloma: Balancing Efficacy, Safety, and BCMA vs. GPRC5D Options

Video content above is prompted by the following:

• What factors make Sarah an ideal candidate for CAR-T therapy in the second-line setting?
  • How does her age, fitness, and early relapse influence your decision?
  • What other treatment options would you consider for this patient?

Recent Videos